Login
Super Investors Velan Capital Investment Management LP
VC

Velan Capital Investment Management LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$105M
Positions
43
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (20 quarters reported)

$220M $97.2M
Q4 21 Q4 22 Q4 23 Q4 24 Q4 25 Q3 26

$129M in Q4 2021 → $105M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
PP Praxis Precision Medicines I 21.3% Trimmed 14% 76,600 $22.3M
Immix Biopharma Inc 10.8% Unchanged 1,085,000 $11.3M
Protara Therapeutics Inc 8.3% Unchanged 2,844,652 $8.68M
Sutro Biopharma Inc 7.8% Trimmed 0.4% 510,038 $8.22M
AS Abivax Sa 6.2% Unchanged 65,630 $6.5M
Maplight Therapeutics Inc 6.1% Added 27% 624,703 $6.37M
Anteris Technologies Global 5.2% Unchanged 700,000 $5.44M
Edesa Biotech Inc 5.2% Added 55% 1,282,045 $5.4M
Avalo Therapeutics Inc 4.7% Unchanged 324,452 $4.97M
Xencor Inc 4.2% Trimmed 31% 175,000 $4.37M
Evommune Inc 3.6% Added 1.1% 456,255 $3.77M
Eupraxia Pharmaceuticals Inc 3.1% Unchanged 352,000 $3.2M
Heron Therapeutics Inc 2.6% Unchanged 8,753,290 $2.74M
Edgewise Therapeutics Inc 1.3% New 34,250 $1.39M
Rein Therapeutics Inc 1.3% Unchanged 1,700,000 $1.37M
Nasus Pharma Ltd 1.3% Unchanged 359,390 $1.33M
Q32 Bio Inc 0.9% New 120,000 $992K
Inspiremd Inc 0.6% Added 524% 924,680 $618K
Protagonist Therapeutics Inc 0.5% Unchanged 3,700 $521K
Aardvark Therapeutics Inc 0.4% New 85,868 $453K
Nurix Therapeutics Inc 0.4% Unchanged 16,000 $379K
Cytomx Therapeutics Inc. 0.3% Unchanged 120,000 $326K
Ovid Therapeutics Inc 0.3% Unchanged 130,000 $324K
Mineralys Therapeutics Inc 0.3% Unchanged 11,000 $276K
Replimune Group Inc 0.3% Unchanged 20,000 $265K
Precision Biosciences Inc 0.2% Unchanged 40,000 $250K
Zai Lab Ltd 0.2% New 9,000 $237K
C4 Therapeutics Inc 0.2% Trimmed 88% 70,000 $233K
M Macrogenics Inc 0.2% Unchanged 60,000 $232K
Immunome Inc 0.2% Unchanged 10,000 $215K
An2 Therapeutics Inc 0.2% Unchanged 40,000 $213K
VT Viridian Therapeutics Inc 0.2% Unchanged 10,000 $206K
CP Corbus Pharmaceuticals Hldgs 0.2% Added 15% 30,000 $205K
Enanta Pharmaceuticals Inc 0.2% New 15,000 $198K
Scynexis Inc 0.2% Unchanged 40,000 $198K
Artiva Biotherapeutics Inc 0.2% Unchanged 25,000 $178K
Rocket Pharmaceuticals Inc 0.2% Unchanged 60,000 $158K
Lyell Immunopharma Inc 0.1% Trimmed 86% 15,000 $147K
Jade Biosciences Inc 0.1% New 10,000 $141K
Neumora Therapeutics Inc. 0.1% Unchanged 230,000 $137K
Tenax Therapeutics Inc Call 0.1% Unchanged 68,700 $130K
Larimar Therapeutics Inc 0.1% Unchanged 33,000 $105K
Kalaris Therapeutics Inc 0.1% Unchanged 25,000 $72.3K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Tenax Therapeutics Inc Exited −549,985 −$8M —
Rezolute Inc Exited −750,000 −$3.9M —
PP Praxis Precision Medicines I Trimmed −12,181 −$3.55M 21.3%
Verrica Pharmaceuticals Inc Exited −471,559 −$2.89M —
Adma Biologics Inc Exited −250,000 −$2.09M —
Xencor Inc Trimmed −80,000 −$2M 4.2%
Edesa Biotech Inc Added +454,545 +$1.91M 5.2%
C4 Therapeutics Inc Trimmed −500,000 −$1.67M 0.2%
Edgewise Therapeutics Inc New +34,250 +$1.39M 1.3%
Maplight Therapeutics Inc Added +131,810 +$1.34M 6.1%

Showing the 10 largest of 30 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
ET Esperion Therapeutics Inc Ne Exited −1,720,000 −$4.71M —
PP Praxis Precision Medicines I Trimmed −12,000 −$4.02M 18.1%
Immix Biopharma Inc Added +345,000 +$3.56M 6.8%
C4 Therapeutics Inc New +570,000 +$2.66M 1.6%
Avalo Therapeutics Inc Added +139,330 +$2.57M 3.7%
Adma Biologics Inc New +250,000 +$2.09M 1.3%
Rein Therapeutics Inc New +1,700,000 +$1.77M 1.1%
Cytomx Therapeutics Inc. Trimmed −420,000 −$1.58M 0.3%
AS Abivax Sa Trimmed −11,370 −$1.52M 5.3%
VT Viridian Therapeutics Inc Trimmed −81,123 −$1.49M 0.1%

Showing the 10 largest of 33 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Cidara Therapeutics Inc Exited −108,404 −$23.9M —
Tenax Therapeutics Inc Added +500,000 +$8M 5.8%
Immix Biopharma Inc Added +705,000 +$6.42M 4.2%
Sutro Biopharma Inc Added +200,160 +$4.99M 8.0%
LH Lantheus Hldgs Inc Exited −74,687 −$4.97M —
Anteris Technologies Global New +700,000 +$3.89M 2.4%
Mineralys Therapeutics Inc Trimmed −140,000 −$3.79M 0.2%
Rapt Therapeutics Inc Exited −108,000 −$3.66M —
Xencor Inc New +250,000 +$3.02M 1.9%
Terns Pharmaceuticals Inc Exited −70,000 −$2.83M —

Showing the 10 largest of 40 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 13, 2026

Company Action Shares changed Value of change % of portfolio
PP Praxis Precision Medicines I Trimmed −32,024 −$9.44M 17.2%
Maplight Therapeutics Inc New +522,305 +$9.17M 5.3%
Evommune Inc New +506,754 +$8.68M 5.0%
ET Esperion Therapeutics Inc Ne New +1,210,000 +$4.48M 2.6%
ZP Zooz Pwr Ltd Exited −2,000,000 −$4.28M —
Verrica Pharmaceuticals Inc New +471,559 +$3.92M 2.3%
Alumis Inc Exited −946,683 −$3.78M —
Protara Therapeutics Inc Added +695,652 +$3.71M 8.8%
Sutro Biopharma Inc New +312,000 +$3.61M 2.1%
Sutro Biopharma Inc Exited −3,120,000 −$2.71M —

Showing the 10 largest of 31 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Tourmaline Bio Inc Trimmed −388,089 −$18.6M 0.3%
V Veronapharmaplc Exited −95,000 −$8.99M —
Z Zevratherapeuticsinc Exited −715,000 −$6.3M —
AS Abivax Sa New +64,389 +$5.47M 5.1%
ZP Zooz Pwr Ltd New +2,000,000 +$4.28M 4.0%
LH Lantheus Hldgs Inc New +73,545 +$3.77M 3.5%
A Arvinasinc Exited −500,000 −$3.68M —
S Scpharmaceuticalsinc Exited −917,668 −$3.5M —
Inspiremd Inc Added +1,239,669 +$2.99M 4.9%
L Liquidiacorporation Exited −239,260 −$2.98M —

Showing the 10 largest of 42 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Acelyrin Inc Exited −3,366,945 −$8.32M —
Springworks Therapeutics Inc Exited −185,520 −$8.19M —
C Cidaratherapeuticsinc New +100,000 +$4.87M 4.8%
A Alumisinc New +1,620,846 +$4.86M 4.8%
A Arvinasinc New +500,000 +$3.68M 3.6%
R Rezoluteinc Added +350,000 +$1.56M 3.3%
P Praxisprecisionmedicinesi Trimmed −35,666 −$1.5M 6.2%
S Sutrobiopharmainc Added +2,030,000 +$1.45M 2.2%
P Protaratherapeuticsinc Added +471,200 +$1.43M 6.4%
N Nektartherapeutics New +50,000 +$1.29M 1.3%

Showing the 10 largest of 38 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Acelyrin Inc New +3,366,945 +$8.32M 8.6%
PP Praxis Precision Medicines I Trimmed −115,000 −$4.36M 7.2%
Verona Pharma PLC Added +45,000 +$2.86M 6.2%
Zevra Therapeutics Inc Added +365,000 +$2.73M 5.1%
Scpharmaceuticals Inc New +917,668 +$2.41M 2.5%
Mineralys Therapeutics Inc New +150,600 +$2.39M 2.5%
Nurix Therapeutics Inc Exited −97,889 −$1.84M —
Edesa Biotech Inc New +687,500 +$1.68M 1.7%
Kura Oncology Inc Exited −150,000 −$1.31M —
Instil Bio Inc New +69,000 +$1.2M 1.2%

Showing the 10 largest of 37 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
SS SPDR Ser Tr Exited −150,000 −$14.8M —
Springworks Therapeutics Inc New +185,520 +$6.7M 5.8%
Protara Therapeutics Inc Added +1,005,000 +$5.31M 7.2%
PP Praxis Precision Medicines I Trimmed −50,666 −$3.9M 19.9%
Scpharmaceuticals Inc Exited −517,668 −$2.36M —
Verona Pharma PLC New +50,000 +$2.32M 2.0%
Replimune Group Inc New +181,367 +$2.2M 1.9%
Tela Bio Inc Exited −747,410 −$1.89M —
Tourmaline Bio Inc Added +92,605 +$1.88M 7.4%
Nurix Therapeutics Inc New +97,889 +$1.84M 1.6%

Showing the 10 largest of 43 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support